Investors Buy High Volume of Call Options on Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) was the recipient of unusually large options trading activity on Wednesday. Stock investors purchased 51,813 call options on the company. This is an increase of approximately 264% compared to the average volume of 14,225 call options.

Insider Transactions at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 13,770 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the sale, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at $3,434,220. This represents a 19.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Ryan Fukushima sold 120,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the completion of the sale, the chief operating officer now directly owns 1,007,207 shares in the company, valued at $42,816,369.57. This trade represents a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,058,072 shares of company stock valued at $90,719,375 in the last 90 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI during the third quarter worth $30,000. FNY Investment Advisers LLC bought a new position in shares of Tempus AI during the fourth quarter worth about $67,000. IFP Advisors Inc bought a new position in shares of Tempus AI during the fourth quarter worth about $76,000. US Bancorp DE acquired a new stake in Tempus AI in the fourth quarter worth about $80,000. Finally, Vestor Capital LLC acquired a new stake in Tempus AI in the third quarter worth about $153,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TEM. Loop Capital cut their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Bank of America upped their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $58.55.

Tempus AI Price Performance

Tempus AI stock opened at $64.99 on Friday. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49. The firm has a 50 day moving average price of $44.36 and a 200 day moving average price of $48.84. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.